Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate.

This was a zebrafish larval model, not a human clinical trial, so the findings do not show what cannabidiol or risperidone would do in patients with autism. Behavioral testing stopped at 7 days post-fertilization, so the paper did not test whether valproate deficits or drug effects persist into later development. The social interaction test did not detect a valproate effect, and the paper states this may be because social behavior regulation is immature at this stage or the assay lacked sensitivity. The supplied text does not report blinding of behavioral scoring or allocation of larvae to drug treatment groups. Several authors have patents, licensing, or agreements related to CBD products, and one author reports relationships with companies including drug suppliers.

Funding came from Fundação de Amparo à Pesquisa do Estado de São Paulo and INCT 2014: Translational Medicine. Several authors are inventors of CBD-related patents, Universidade de São Paulo licensed a patent to Phytecs Pharm, and authors have an agreement with Prati-Donaduzzi to develop a synthetic CBD pharmaceutical product. One author reports consulting, speaker fees, advisory board membership, or research funding from companies including Prati-Donaduzzi and BSPG Pharm.

Do not conclude that cannabidiol is a safer or more effective autism treatment than risperidone for people. The study used zebrafish larvae, not human patients, and measured swimming, aggression, biochemical markers, and developmental changes at an early larval stage. It did not test autism symptoms, communication, daily function, or long-term clinical outcomes.